Article · 13 Feb 2026
Conference abstractPublished 23 Nov 2012
Regulatory frame work for biosimilar monoclonal antibodies
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The objective of this paper is to facilitate regulatory requirements for the approval process of Biosimilar Monoclonal antibodies (mAb) in Regulated and Emerging markets. Biosimilars are biological products that are the replicas of their innovator biopharmaceuticals. Monoclonal antibodies have been established as a major product class of biotechnology-derived medicinal products. Specified regulations, and approval process of generic version of mAb exists depending on the country. In European Union, Centralized Procedure is mandatory for Biosimilar (mAb). When compared with other countries EMA (European medicines agency) has proper regulations pertaining to Biosimilar mAbs. In US proper set of guidelines for Biosimilar (mAb) have evolved after ?Promoting Innovation and Access to life-saving Medicines Act? introduced, authorized USFDA to approve followon biologics/biosimilars in an abbreviated manner. The approval process is abbreviated biosimilar biologics license applications (bBLAs) or 351(k) filings. In India, the product is under new drugs, and follows the Biological drugs submission requirements. In India, apart from Central Drugs Standard Control Organization (CDSCO), the office of Drug Controller General of India (DCGI) the apex regulatory body under Government of India (GoI), two other competent authorities are involved in the approval process of biosimilars or Similar Biologics products (SBPs). It is a big difficulty to Biosimilar mAb potential producers to fallow different approval processes and regulations in different regions. This paper concludes that there is a need that ICH/WHO should come forward and lay down proper and specific regulations for these products.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “K. Sreekanth Reddy”

